Regulatory approval timelines uncertain
EU marketing authorizations follow 210 working day standard timeline, with query-driven stop clocks adding uncertainty. Obtaining approval slots in Europe is described as the primary challenge.
SAKAR / Q3-FY26 / risks
Keep the risk register visible.
Sakar Healthcare · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Competitive intensity in TKI portfolio
Another Indian pharma player with TKI focus has achieved meaningful EU revenue traction. Sakar's competitiveness depends on partner selection and market penetration in respective European territories.
Partner-dependent commercialization
Sakar relies on partners (Accord, Torrent UK, Glenmark, Zydus, Hyman Germany) for EU market access. First commercial supply to Bulgaria/Bosnia faces 90-150 day lead times; margins on Accord business at 24-26% EBITDA.
Tax rate normalization post-FY27
Lower tax provision (18-19%) due to MAT credit utilization will normalize to ~25% post-FY27, creating a potential headwind to net income growth.